U.S. Markets open in 6 hrs 26 mins

ARIAD strength attributed to inclusion on EMA meeting agenda

The European Medicines Agency will review Ariad's Iclusig at its December meeting, according to a meeting agenda posted to the regulator's website. Ariad shares are up 9.8% to $4.24 following circulation of the agenda.